More generic drug competitors don't always mean lower prices. Real-world data shows how patents, PBMs, complex formulations, and regulatory policies distort competition - often keeping prices high despite dozens of approved generics.
learn moreUpcoming patent expirations for blockbuster biologics like Keytruda and Eylea are set to unleash a wave of biosimilars, potentially saving the U.S. healthcare system hundreds of billions. Here’s what’s coming, who’s entering the market, and how it will change patient access.
learn more